Equities research analysts expect Opko Health Inc. (NASDAQ:OPK) to post ($0.08) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Opko Health’s earnings, with the lowest EPS estimate coming in at ($0.10) and the highest estimate coming in at ($0.05). Opko Health reported earnings per share of ($0.04) during the same quarter last year, which would suggest a negative year over year growth rate of 100%. The business is scheduled to announce its next earnings report on Wednesday, March 7th.
According to Zacks, analysts expect that Opko Health will report full year earnings of ($0.27) per share for the current year, with EPS estimates ranging from ($0.34) to ($0.22). For the next year, analysts anticipate that the company will report earnings of ($0.17) per share, with EPS estimates ranging from ($0.24) to ($0.06). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that follow Opko Health.
OPK has been the subject of several research analyst reports. BidaskClub cut Opko Health from a “hold” rating to a “sell” rating in a research report on Saturday, November 11th. Zacks Investment Research cut Opko Health from a “hold” rating to a “sell” rating in a research report on Wednesday, January 24th. Finally, Cantor Fitzgerald set a $20.00 price objective on Opko Health and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $13.34.
In other Opko Health news, CEO Phillip Md Et Al Frost acquired 100,000 shares of the business’s stock in a transaction on Wednesday, January 24th. The stock was purchased at an average price of $4.89 per share, for a total transaction of $489,000.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $15,007,170.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders acquired 688,000 shares of company stock valued at $2,970,260 in the last quarter. 40.19% of the stock is currently owned by company insiders.
Hedge funds have recently made changes to their positions in the company. Crossmark Global Holdings Inc. purchased a new stake in Opko Health during the 3rd quarter worth about $118,000. State of Alaska Department of Revenue purchased a new stake in Opko Health during the 4th quarter worth about $144,000. The Manufacturers Life Insurance Company increased its position in Opko Health by 7.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,535 shares of the biotechnology company’s stock worth $149,000 after purchasing an additional 1,657 shares in the last quarter. First Trust Advisors LP purchased a new stake in Opko Health during the 4th quarter worth about $154,000. Finally, Balyasny Asset Management LLC increased its position in Opko Health by 78.7% during the 2nd quarter. Balyasny Asset Management LLC now owns 40,262 shares of the biotechnology company’s stock worth $265,000 after purchasing an additional 17,728 shares in the last quarter. Institutional investors and hedge funds own 22.68% of the company’s stock.
About Opko Health
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.